OraSure Technologies, Inc. (OSUR) Stock Analysis

OraSure (OSUR) Q2 2026 Earnings Call Transcript

Thu, August 13, 2026 at 12:15 AM UTC 4 min read

OraSure Technologies (OSUR) reported its Q2 2026 earnings, revealing a significant increase in revenue driven by strong demand for its COVID-19 testing products. The company also highlighted advancements in its oral fluid diagnostics, which could enhance future growth prospects. This performance is crucial for investors, as it demonstrates OSUR's resilience and potential for continued profitability in a competitive healthcare market.

Read full article →

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

Thu, June 11, 2026 at 12:00 PM UTC 2 min read

OraSure Technologies, Inc. received FDA clearance for its new testing solution, enhancing patient-friendly access to sexually transmitted infection (STI) testing. This development is significant for investors as it positions the company to capture a larger market share in the growing demand for accessible STI testing, potentially driving revenue growth. The clearance underscores OraSure's commitment to innovation in healthcare, which may positively influence investor confidence and stock performance.

Read full article →